FDA APPROVES TILTAN’S INVESTIGATIONAL NEW DRUG
(IND) CLINICAL TRIAL PROGRAM 21.12.2010
Jerusalem, Israel – December 21, 2010 - - Tiltan Pharma Ltd. is pleased to announce it has received a
favourable review from the U.S. FDA which will allow for the launch a of U.S. based clinical study using
Tiltan’s emerging strategy for cancer treatment, a patented, mechanism based designed anti-angiogenic
drug combination using FDA approved drugs that target different, non-overlapping pathways of the
angiogenic process.
Tiltan is conducting an FDA approved Phase IIb global clinical study for Castration Resistant Prostate
Cancer (“CRPC”) which will be based in Israel, Russia and the United States. The focus of the study will
be on safety and efficacy of Tiltan’s anti—angiogenic drug combination. Israeli trials are currently
underway and now that FDA approval has been granted Tiltan intends to expand the study to the United
States at Johns Hopkins in Baltimore, Maryland
“We are very pleased to announce the U.S. launch of the Phase IIb study for CRPC and look forward to
extending the encouraging data we have compiled to date in a formal manner through this study”, said
Dr. Dan Goldstaub, Tiltan’s Chief Operating Officer.
Tiltan, founded in 2005 and derived from Hebrew University’s technology transfer division, Yissum, has
raised approximately $3 million since 2005 from a group of high net worth investors in both Israel and
Canada as well as having been awarded an additional $2 million from the Office of the Chief Scientist of
Israel.
To date, the company has successfully demonstrated, through a Phase I and IIa clinical study, both safety
and tolerability for patients with various indications of solid tumors, including Prostate, Ovarian and
Sarcomas.
About Tiltan Pharma
Tiltan Pharma Ltd. is dedicated to the development and commercialization of a proprietary anti-angiogenic
platform for the treatment of cancer and other indications. Tiltan’s proprietary anti-cancer platform is based
on a combination of agents that target different, non-overlapping aspects of the angiogenic process. All
of these agents are orally bio-available and FDA approved.